Holen Sie sich die Stockscreener-App
122.09
2.39%
-2.99
Handel nachbörslich:
122.09
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$125.08
Offen:
$124.62
24-Stunden-Volumen:
6.38M
Relative Volume:
1.04
Marktkapitalisierung:
$212.30B
Einnahmen:
$43.84B
Nettoeinkommen (Verlust:
$13.90B
KGV:
15.31
EPS:
7.9725
Netto-Cashflow:
$6.92B
1W Leistung:
-4.62%
1M Leistung:
-3.38%
6M Leistung:
-8.60%
1J Leistung:
+5.61%
1-Tages-Spanne:
$121.71
$124.62
1-Wochen-Bereich:
$121.71
$128.99
52-Wochen-Spanne:
$110.86
$140.84
Abbott Laboratories Stock (ABT) Company Profile
Firmenname
Abbott Laboratories
Sektor
Branche
Telefon
(224) 667-6100
Adresse
100 ABBOTT PARK ROAD, ABBOTT PARK, IL
Vergleichen Sie ABT mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ABT
Abbott Laboratories
|
122.09 | 217.50B | 43.84B | 13.90B | 6.92B | 7.9725 |
|
BSX
Boston Scientific Corp
|
93.84 | 144.57B | 19.35B | 2.78B | 3.82B | 1.8696 |
|
SYK
Stryker Corp
|
353.60 | 139.21B | 24.38B | 2.94B | 4.07B | 7.6159 |
|
MDT
Medtronic Plc
|
101.26 | 129.94B | 34.76B | 4.79B | 5.21B | 3.7017 |
|
EW
Edwards Lifesciences Corp
|
84.32 | 50.02B | 5.88B | 1.34B | 799.60M | 2.3489 |
Abbott Laboratories Stock (ABT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-10 | Eingeleitet | The Benchmark Company | Buy |
| 2025-07-18 | Hochstufung | Jefferies | Hold → Buy |
| 2025-06-16 | Eingeleitet | Leerink Partners | Market Perform |
| 2024-10-08 | Eingeleitet | Oppenheimer | Outperform |
| 2024-09-19 | Eingeleitet | Piper Sandler | Overweight |
| 2024-07-30 | Herabstufung | Edward Jones | Buy → Hold |
| 2024-05-30 | Eingeleitet | Goldman | Buy |
| 2023-07-21 | Hochstufung | Wolfe Research | Underperform → Peer Perform |
| 2023-05-30 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2023-04-20 | Bestätigt | Barclays | Overweight |
| 2023-04-20 | Bestätigt | Bernstein | Outperform |
| 2023-04-20 | Bestätigt | JP Morgan | Overweight |
| 2023-04-20 | Bestätigt | Raymond James | Outperform |
| 2023-04-20 | Bestätigt | UBS | Buy |
| 2023-04-20 | Bestätigt | Wolfe Research | Underperform |
| 2023-03-29 | Eingeleitet | UBS | Buy |
| 2022-10-26 | Eingeleitet | Mizuho | Neutral |
| 2022-10-18 | Eingeleitet | Barclays | Overweight |
| 2022-10-12 | Eingeleitet | Jefferies | Hold |
| 2022-07-06 | Eingeleitet | Wolfe Research | Underperform |
| 2022-03-02 | Fortgesetzt | BofA Securities | Buy |
| 2022-01-27 | Bestätigt | Credit Suisse | Outperform |
| 2022-01-27 | Bestätigt | Morgan Stanley | Overweight |
| 2022-01-27 | Bestätigt | Raymond James | Outperform |
| 2022-01-27 | Bestätigt | UBS | Buy |
| 2021-12-10 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2021-10-27 | Hochstufung | Atlantic Equities | Neutral → Overweight |
| 2021-10-14 | Eingeleitet | Redburn | Neutral |
| 2021-05-25 | Eingeleitet | Barclays | Overweight |
| 2021-04-15 | Eingeleitet | Atlantic Equities | Neutral |
| 2021-01-28 | Hochstufung | BTIG Research | Neutral → Buy |
| 2020-09-11 | Eingeleitet | Wolfe Research | Outperform |
| 2020-06-01 | Herabstufung | Goldman | Neutral → Sell |
| 2020-03-05 | Eingeleitet | Citigroup | Buy |
| 2020-02-13 | Eingeleitet | Goldman | Neutral |
| 2020-02-06 | Fortgesetzt | BTIG Research | Neutral |
| 2020-01-02 | Herabstufung | Guggenheim | Buy → Neutral |
| 2019-06-13 | Bestätigt | BofA/Merrill | Buy |
| 2019-02-07 | Bestätigt | BofA/Merrill | Buy |
| 2019-01-02 | Herabstufung | Citigroup | Neutral → Sell |
| 2018-11-30 | Hochstufung | Goldman | Neutral → Buy |
| 2018-10-16 | Eingeleitet | Barclays | Overweight |
| 2018-06-27 | Eingeleitet | Bernstein | Outperform |
| 2018-01-30 | Bestätigt | Citigroup | Neutral |
| 2018-01-25 | Bestätigt | Stifel | Buy |
| 2018-01-25 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2018-01-03 | Eingeleitet | Evercore ISI | Outperform |
| 2018-01-02 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2018-01-02 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2017-10-19 | Bestätigt | RBC Capital Mkts | Outperform |
| 2017-10-19 | Bestätigt | Stifel | Buy |
Alle ansehen
Abbott Laboratories Aktie (ABT) Neueste Nachrichten
Abbott (ABT) Expands Lingo Glucose Monitor to Android Users - GuruFocus
Lilly’s GLP-1 Surge Dwarfs Abbott’s Steady Device Growth With 54% Revenue Jump - AOL.com
Abbott (NYSE: ABT) adds Lingo to Android, cites 15% lower odds of glucose spikes - Stock Titan
SVB Wealth LLC Has $12.17 Million Stake in Abbott Laboratories $ABT - MarketBeat
Divergent Views Emerge on Abbott Laboratories’ Stock Valuation - AD HOC NEWS
The Minnesotan behind Cologuard, which fueled the biggest health care acquisition of 2025 - Star Tribune
University of Wisconsin Wins Abbott and Big Ten's 'We Give Blood' Competition as Campaign Donations Surge 319%, Helping Save Nearly 250,000 Lives - Finviz
Abbott (ABT) awards $1 million as Big Ten drive logs 83,043 blood donations - Stock Titan
Seaview Investment Managers LLC Purchases New Stake in Abbott Laboratories $ABT - MarketBeat
UBS Reaffirms Buy Rating on Abbott Laboratories (ABT) Amid Exact Sciences Acquisition - MSN
Why Is Adaptive Biotechnologies Stock Trading Lower After Natera's Over $400 Million Deal? - Benzinga
Is Abbott Laboratories Fairly Priced After Growth In Devices And Diagnostics? - Yahoo Finance
FDA Warning For Abbott Glucose Sensors After 700 Injuries, 7 DeathsAbbott Laboratories (NYSE:ABT) - Benzinga
Healthtech Market Is Booming Worldwide With Boston Scientific, Philips Healthcare, Abbott Laboratories, - EIN News
Guggenheim Capital LLC Buys 11,794 Shares of Abbott Laboratories $ABT - MarketBeat
Assessing Abbott After 10.5% Gains and DCF PE Signals Amid Exact Sciences Deal Talk - simplywall.st
The Zacks Analyst Blog Highlights HSBC, Abbott, Shell and Oak Valley - Yahoo Finance
Arrowstreet Capital Limited Partnership Purchases 291,987 Shares of Abbott Laboratories $ABT - MarketBeat
Abbott Laboratories (NYSE:ABT) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Diabetes Glucose Monitors Recalled After 7 Deaths and More Than 700 Injuries - People.com
Top Analyst Reports for HSBC, Abbott & Shell - Yahoo Finance
Medtronic launches new diabetes tech integrated with Abbott sensor - Cardiovascular Business
FDA Issues Warning on Abbott (ABT) Glucose Monitors After Reported Deaths - GuruFocus
How Abbott Laboratories (ABL) stock trades after rate cuts2025 Trade Ideas & Fast Exit and Entry Trade Guides - Newser
Faulty Glucose Monitor Sensors May Be Tied to 7 Deaths, F.D.A. Says - The New York Times
Abbott Launches Two New Ensure Max Protein Shakes to Tap into Growing Muscle Health Movement - marketscreener.com
Molecular Cytogenetics Market Intelligence Report (2020-2030) Featuring Key Players Danaher, MetaSystems, Agilent Technologies, Abbott Labs, Bio-Rad Labs and MoreResearchAndMarkets.com - The AI Journal
Muscles, the New Flex: Abbott Launches Two New Ensure Max Protein Shakes to Tap into Growing Muscle Health Movement - Finviz
Abbott (NYSE: ABT) debuts Ensure Max Protein 42g, 2 in 1 shakes with Walmart rollout - Stock Titan
Millions of Abbott Glucose Sensors Recalled After Faulty Readings Linked to Deaths - The Suburban
Abbott - The Pharma Letter
Don't Ignore The Insider Selling In Abbott Laboratories - simplywall.st
Abbott Laboratories $ABT Stake Lifted by First Trust Advisors LP - MarketBeat
Baird Financial Group Inc. Grows Stock Holdings in Abbott Laboratories $ABT - MarketBeat
Medtronic launches insulin delivery system with Abbott-made sensor - MedTech Dive
Abbott Laboratories' (NYSE:ABT) Price Is Right But Growth Is Lacking - 富途牛牛
Seven States Join Abbott Infant Formula FCA Lawsuit, Alleging Years of Violations and Cover-Ups - USA Herald
Abbott Defends Glucose Monitor Patents In Sinocare Fight - Law360
Abbott Laboratories (NYSE: ABT) sees Vanguard report 10.05% beneficial stake - Stock Titan
The US Rollout of MiniMed 780G With Abbott's Sensor May Lift MDT Stock - sharewise.com
7 deaths, hundreds of injuries may be linked to diabetes glucose monitor errors, FDA says - CBS News
Abbott Laboratories (ABT) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance
M&T Bank Corp Trims Stake in Abbott Laboratories $ABT - MarketBeat
Shelton Capital Management Has $8.97 Million Stake in Abbott Laboratories $ABT - MarketBeat
Loomis Sayles & Co. L P Raises Position in Abbott Laboratories $ABT - MarketBeat
Can Abbott Laboratories stock weather global recessionForecast Cut & AI Based Buy and Sell Signals - Newser
Invesco Ltd. Increases Stock Holdings in Abbott Laboratories $ABT - MarketBeat
States Hit Abbott With FCA Suit Over Infant Formula Recall - Law360
7 deaths linked to faulty blood glucose monitors as FDA issues safety warning - Fox Business
Seven deaths linked to malfunctioning glucose monitors - USA Today
Medtronic begins U.S. commercial launch of the MiniMed™ 780G system with the Instinct sensor, made by Abbott - Medtronic
Finanzdaten der Abbott Laboratories-Aktie (ABT)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.77%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):